GlucoTrack (NASDAQ:GCTK) Earns “Sell (E+)” Rating from Weiss Ratings

GlucoTrack (NASDAQ:GCTK)‘s stock had its “sell (e+)” rating reaffirmed by Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded shares of GlucoTrack to a “sell” rating in a research note on Saturday, June 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, GlucoTrack presently has a consensus rating of “Sell”.

GlucoTrack Trading Up 14.9%

GCTK opened at $8.56 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.27 and a quick ratio of 3.27. GlucoTrack has a fifty-two week low of $4.22 and a fifty-two week high of $2,928.00. The firm has a market capitalization of $7.70 million, a PE ratio of -0.15 and a beta of 0.22. The company’s 50-day moving average is $5.96 and its 200 day moving average is $7.67.

GlucoTrack (NASDAQ:GCTK) last posted its earnings results on Thursday, August 14th. The company reported ($9.62) earnings per share for the quarter.

Institutional Investors Weigh In On GlucoTrack

An institutional investor recently raised its position in GlucoTrack stock. Bank of America Corp DE lifted its stake in shares of GlucoTrack, Inc. (NASDAQ:GCTK) by 102,125.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,089 shares of the company’s stock after purchasing an additional 4,085 shares during the period. Bank of America Corp DE owned 0.85% of GlucoTrack worth $25,000 at the end of the most recent quarter. Institutional investors own 10.92% of the company’s stock.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.